3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
40
Triple Negative Breast Neoplasms
16
Carcinoma, Transitional Cell
14
Breast Neoplasms
14
Small Cell Lung Carcinoma
12
Urinary Bladder Neoplasms
11
Melanoma
10
Carcinoma, Hepatocellular
9
Neoplasms
8
Carcinoma, Renal Cell
8
Uterine Cervical Neoplasms
6
Neoplasm Metastasis
6
Lung Neoplasms
6
Colorectal Neoplasms
5
Ovarian Neoplasms
4
Lymphoma, Follicular
4
Lymphoma
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Prostatic Neoplasms
3
Leukemia, Myeloid, Acute
3
Cholangiocarcinoma
3
Brain Neoplasms
3
Stomach Neoplasms
2
Solid Tumors
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Kidney Neoplasms
2
Gallbladder Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
Gemcitabine
13
Cisplatin
8
Capecitabine
8
Fluorouracil
5
pembrolizumab
4
Oxaliplatin
4
Sorafenib
3
Leucovorin
3
Erlotinib Hydrochloride
3
trametinib
2
regorafenib
2
durvalumab
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
trifluridine tipiracil drug combination
1
tremelimumab
1
spartalizumab
1
seribantumab
1
olutasidenib
1
olaparib
1
devimistat
1
derazantinib
1
dehydroftorafur
1
cediranib
1
cabozantinib
1
Trifluridine
1
Trastuzumab
1
Therapeutics
1
Sutures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Bile Duct Neoplasms
×
atezolizumab
×
Clear all
No trials found.